Latest news
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - StocktwitsStocktwits · Fri, 07 Aug 2026 04:41:29 GMTNCCN Guidelines: Navigating ctDNA MRD Testing in Evolving MIBC Paradigms - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 18:04:30 GMTNCCN visits St. Francis, part 3: The peace pole and 'What’s a Portiuncula?’ - Diocese of RaleighDiocese of Raleigh · Wed, 05 Aug 2026 12:00:00 GMTNavigating ctDNA-Guided Decision-Making in Muscle-Invasive Bladder Cancer - CancerNetworkCancerNetwork · Tue, 04 Aug 2026 22:09:15 GMTNCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer - OncLiveOncLive · Mon, 03 Aug 2026 15:13:18 GMTGedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2– Breast Cancer - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 12:08:52 GMTNewly FDA-approved Revtorpyk wins NCCN listing - The Pharma LetterThe Pharma Letter · Sat, 01 Aug 2026 14:27:59 GMTNCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 15:09:03 GMT